SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, ...
* Neogenomics reports record revenue of $66.1 million on 16% volume growth and 13% reduction in average cost per test in the second quarter of 2017 * Q2 adjusted earnings per share $0.04 * Q2 revenue ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services ...
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results